Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19029026 | EPINEPHRINE LIQUID FORMULATIONS | January 2025 | September 2025 | Allow | 8 | 1 | 0 | No | No |
| 19026269 | POROUS HYDROGEL MICROSPHERES AND PREPARATION METHODS THEREOF | January 2025 | February 2026 | Abandon | 13 | 2 | 0 | No | No |
| 18926688 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | October 2024 | August 2025 | Allow | 10 | 2 | 1 | Yes | No |
| 18664846 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | May 2024 | June 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18654460 | Pharmaceutical Formulation | May 2024 | February 2026 | Abandon | 21 | 1 | 0 | No | No |
| 18642595 | FORMULATIONS OF TEGAVIVINT | April 2024 | August 2025 | Allow | 16 | 1 | 0 | No | No |
| 18608748 | DOSAGE FORMS OF MIRDAMETINIB | March 2024 | February 2026 | Abandon | 23 | 2 | 0 | No | No |
| 18436072 | PHOSPHODIESTERASE-5 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | February 2024 | November 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18424936 | INSULIN FORMULATIONS AND METHODS OF USING SAME IN PRETERM INFANTS | January 2024 | May 2025 | Allow | 16 | 3 | 1 | Yes | No |
| 18422456 | PHARMACOKINETICS OF COMBINED RELEASE FORMULATIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE | January 2024 | March 2026 | Allow | 26 | 3 | 1 | Yes | No |
| 18422105 | MYCOPHENOLATE ORAL SUSPENSION | January 2024 | February 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18420901 | AMLODIPINE FORMULATIONS | January 2024 | June 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18421426 | MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE | January 2024 | May 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18391451 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | December 2023 | September 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18529978 | APPARATUS, METHODS, AND SYSTEMS FOR PROVIDING PHARMACEUTICAL COMPOSITIONS AND ADMINISTERING MEDICATIONS TO PATIENTS | December 2023 | September 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18513181 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | November 2023 | December 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18501714 | PHARMACEUTICAL FORMULATIONS | November 2023 | December 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18383389 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | October 2023 | September 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18377216 | PHARMACEUTICAL COMPOSITIONS COMPRISING MARALIXIBAT AND USES THEREOF | October 2023 | March 2025 | Allow | 18 | 3 | 1 | No | No |
| 18474553 | POLYMERIZED WHEY PROTEIN ENCAPSULATED ANTIOXIDANT COMPOUND AND A PROCESS FOR PREPARATION OF SAME | September 2023 | November 2024 | Allow | 14 | 1 | 0 | No | No |
| 18455799 | DISSOLVABLE-CHEWABLE EXHAUSTED-TOBACCO TABLET | August 2023 | March 2026 | Allow | 31 | 4 | 0 | Yes | No |
| 18455001 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | August 2023 | October 2024 | Allow | 14 | 2 | 0 | No | No |
| 18450882 | FORMULATIONS OF NEBIVOLOL | August 2023 | July 2025 | Allow | 23 | 4 | 0 | No | No |
| 17928278 | PHARMACEUTICAL FORMULATIONS OF PILOCARPINE R-(+)-LIPOATE | July 2023 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18216536 | FORMULATIONS OF TRIPHENYL CALCILYTIC COMPOUNDS | June 2023 | March 2025 | Allow | 20 | 2 | 0 | No | No |
| 18337729 | SOLID NANOPARTICLE WITH INORGANIC COATING | June 2023 | September 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18209954 | Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof | June 2023 | November 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18256035 | DELAYED SUSTAINED-RELEASE ORAL DRUG DOSAGE FORMS OF A JANUS KINASE (JAK) INHIBITOR AND METHODS OF USE | June 2023 | March 2026 | Abandon | 33 | 1 | 0 | No | No |
| 18203134 | OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | May 2023 | July 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18203266 | AMLODIPINE FORMULATIONS | May 2023 | December 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18324946 | SELF-ASSEMBLED GELS FOR CONTROLLED DELIVERY OF BIOLOGICS AND METHODS OF MAKING THEREOF | May 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18142667 | HOT MELT EXTRUSION FOR PHARMACEUTICAL VAGINAL FILM PRODUCTS | May 2023 | January 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18138473 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | April 2023 | March 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18113939 | FORMULATIONS OF CALCIUM AND PHOSPHATE FOR ORAL INFLAMMATION | February 2023 | July 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18106193 | FORMULATIONS OF TEGAVIVINT | February 2023 | December 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 18159320 | OROMUCOSAL FILM COMPOSITIONS COMPRISING EPINEPHRINE PARTICLES | January 2023 | August 2025 | Abandon | 31 | 4 | 1 | Yes | No |
| 18099831 | NOVEL COATING COMPOSITION AND COATED COMPOSITIONS COMPRISING THE SAME | January 2023 | July 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18075283 | FOAM COMPOSITIONS, FOAM MATRICES AND METHODS | December 2022 | August 2024 | Allow | 20 | 1 | 0 | No | No |
| 18059470 | MICROCAPSULE POWDER STABLE IN GASTRIC ACID, METHOD FOR PREPARING SAME, AND USE THEREOF | November 2022 | July 2023 | Allow | 18 | 1 | 0 | No | No |
| 17984939 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | November 2022 | September 2024 | Abandon | 22 | 1 | 1 | No | No |
| 18053010 | SOFT GEL CAPSULE COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR | November 2022 | March 2025 | Abandon | 28 | 3 | 0 | No | No |
| 17978780 | CAPSULES WITH OPACIFIER | November 2022 | November 2023 | Allow | 12 | 1 | 0 | No | No |
| 17974316 | PHARMACOKINETICS OF COMBINED RELEASE FORMULATIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE | October 2022 | November 2023 | Allow | 13 | 1 | 0 | Yes | No |
| 17969972 | INSTANT RELEASE PHARMACEUTICAL PREPARATION OF ANTICOAGULANT AND PREPARATION METHOD THEREFOR | October 2022 | November 2023 | Allow | 13 | 1 | 0 | No | No |
| 17962149 | NANOFIBER SCAFFOLDS | October 2022 | July 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17959032 | BISMUTH-THIOL COMPOSITIONS AND METHODS OF USE | October 2022 | July 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17954217 | METHODS OF ASSESSING SUITABILITY OF USE OF PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND POORLY WATER SOLUBLE DRUG | September 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 17934566 | OROMUCOSAL FILM COMPOSITIONS COMPRISING EPINEPHRINE PARTICLES | September 2022 | August 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17933262 | FORMULATIONS CONTAINING EXPECTORANTS OR DECONGESTANTS | September 2022 | February 2024 | Allow | 17 | 0 | 0 | No | No |
| 17946849 | HYDROGEL-BASED BIOLOGICAL DELIVERY VEHICLE | September 2022 | June 2025 | Allow | 33 | 3 | 0 | No | No |
| 17944432 | IMPLANTABLE MEDICAL DEVICES COMPRISING BIO-DEGRADABLE ALLOYS WITH ENHANCED DEGRADATION RATES | September 2022 | March 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17903074 | INSULIN FORMULATIONS AND METHODS OF USING SAME IN PRETERM INFANTS | September 2022 | September 2023 | Allow | 12 | 2 | 0 | No | No |
| 17802197 | DEGRADATIVE METHOD | August 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17892738 | AMLODIPINE FORMULATIONS | August 2022 | March 2023 | Allow | 6 | 1 | 0 | No | No |
| 17890506 | WATER-SOLUBLE PERSONAL CLEANSING PRODUCT, USES, METHODS AND KIT | August 2022 | October 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17876955 | AUTONOMIC NERVE REGULATOR AND COGNITIVE FUNCTION IMPROVER | July 2022 | July 2025 | Allow | 35 | 4 | 0 | Yes | No |
| 17860927 | NANOFORMULATION WITH DIVERSE FUNCTIONAL MOLECULES FROM TURMERIC AND PROCESS FOR PREPARATION OF THE SAME | July 2022 | July 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17855327 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | June 2022 | March 2024 | Allow | 21 | 1 | 0 | No | No |
| 17843097 | MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE | June 2022 | November 2023 | Allow | 17 | 1 | 0 | No | No |
| 17839128 | PRESSURIZED NUTRITIONAL SUPPLEMENT DELIVERY | June 2022 | January 2024 | Abandon | 19 | 1 | 1 | No | No |
| 17832416 | DIRECT APPLICATION SYSTEM AND METHOD FOR THE DELIVERY OF BIOACTIVE COMPOSITIONS AND FORMULATIONS | June 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17756720 | SOLID PHARMACEUTICAL FORMULATIONS OF 6-(2-CHLORO-6-METHYLPYRIDIN-4-YL)-5-(4-FLUOROPHENYL)-1,2,4-TRIAZIN-3-AMINE | June 2022 | August 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17745058 | BIOPHOTONIC COMPOSITIONS FOR TREATING SKIN AND SOFT TISSUE WOUNDS HAVING EITHER OR BOTH NON-RESISTANT AND RESISTANT INFECTIONS | May 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17765211 | UV BLOCKING COMPOSITION COMPRISING RED ALGAE-DERIVED FLORIDOSIDE AND AMINE GROUP-CONTAINING COMPOUND | April 2022 | June 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17727651 | Nitric oxide generation, dilution, analysis, and topical application compositions, systems, apparatus and methods | April 2022 | July 2025 | Abandon | 39 | 3 | 0 | No | No |
| 17727630 | NITRIC OXIDE GENERATION, DILUTION, AND TOPICAL APPLICATION COMPOSITIONS, SYSTEMS, APPARATUS AND METHODS | April 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17658849 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF NAPROXEN SODIUM AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN | April 2022 | March 2024 | Allow | 23 | 1 | 1 | No | No |
| 17711602 | FORMULATION OF INTRINSICALLY ACID-RESISTANT VEGETARIAN-BASED AND GELATIN-BASED SOFT GEL CAPSULES FOR PHARMACEUTICAL/ NUTRACEUTICAL PRODUCTS | April 2022 | February 2025 | Abandon | 34 | 3 | 1 | No | No |
| 17705993 | Volatile Organic Compound Formulations Having Antimicrobial Activity | March 2022 | May 2024 | Allow | 26 | 2 | 1 | No | No |
| 17762420 | AN ANTIPERSPIRANT COMPOSITION | March 2022 | March 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17698609 | PHARMACOKINETICS OF COMBINED RELEASE FORMULATIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE | March 2022 | October 2022 | Allow | 7 | 2 | 0 | Yes | No |
| 17680654 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | February 2022 | September 2023 | Allow | 18 | 3 | 0 | No | No |
| 17637129 | SPHINGOLIPID-BASED SELENIUM COMPOUNDS, METHODS FOR THEIR PREPARATION, AND PHARMACEUTICAL USES THEREOF, INCLUDING AS ANTITUMOR AGENTS | February 2022 | July 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17634758 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | February 2022 | October 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17668811 | Pharmaceutical Composition | February 2022 | December 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17633229 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | February 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17633129 | FILM-FORMING COMPOSITION | February 2022 | December 2025 | Abandon | 46 | 3 | 0 | No | No |
| 17573732 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | January 2022 | August 2023 | Allow | 19 | 1 | 0 | No | No |
| 17569881 | ARTICLES AND METHODS FOR ADMINISTRATION OF THERAPEUTIC AGENTS | January 2022 | August 2024 | Allow | 31 | 4 | 1 | Yes | No |
| 17597220 | THERAPEUTIC USES OF OXIDISING HYPOTONIC ACID SOLUTIONS | December 2021 | January 2026 | Allow | 49 | 2 | 1 | No | No |
| 17560192 | COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL ABSORPTION OF ELECTROLYTES | December 2021 | September 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17560155 | ANTI-TUMOR PLATINUM-BASED DRUG MINERALIZED PROTEIN NANOPARTICLE, PREPARATION METHOD THEREFOR AND USE THEREOF | December 2021 | June 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17556354 | POWDER PREPARATION FOR NASAL ADMINISTRATION | December 2021 | June 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17553507 | FABRICATION OF PROTEIN-ENCAPSULATING MICROGELS | December 2021 | March 2025 | Allow | 39 | 4 | 0 | Yes | No |
| 17618111 | SYNTHESIS AND PURIFICATION OF CANNABIGEROL AND ITS APPLICATION | December 2021 | August 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17533033 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | November 2021 | September 2022 | Allow | 10 | 2 | 0 | Yes | No |
| 17455757 | METHOD FOR IMPROVING THE SENSORIAL PROPERTIES OF OIL-IN-WATER EMULSIONS | November 2021 | March 2025 | Allow | 40 | 5 | 0 | Yes | No |
| 17531032 | SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE | November 2021 | October 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17528678 | COMPOSITIONS AND METHODS RELATING TO MOLECULAR CERIUM-OXIDE NANOCLUSTERS | November 2021 | March 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17595145 | PROCESS FOR PREPARING FILLED HARD-SHELL CAPSULES WITH (METH)ACRYLATE COPOLYMER BASED COATINGS WITH A CAPSULE-FILLING MACHINE | November 2021 | August 2022 | Allow | 9 | 1 | 0 | Yes | No |
| 17522334 | COMPOSITE CHITOSAN-TANNIN-ACTIVE AGENT COMPOSITIONS AND METHODS OF MAKING AND USING SAME | November 2021 | February 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17594739 | COSMETIC COMPOSITIONS IN A SOFT-SOLID FORMAT COMPRISING A HYDROPHOBIC POWDER SELECTED FROM SILICA AEROGEL AND POLYLACTIC ACID, STARCH AND AN UV-FILTER SYSTEM | October 2021 | January 2026 | Abandon | 50 | 4 | 0 | No | No |
| 17502932 | SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION | October 2021 | February 2022 | Allow | 4 | 1 | 0 | No | No |
| 17497860 | Enteric Use of Potassium Permanganate in Humans and Animals | October 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17497660 | IBUPROFEN AND FAMOTIDINE TABLET | October 2021 | March 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17494749 | MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE | October 2021 | June 2022 | Allow | 8 | 2 | 1 | Yes | No |
| 17494455 | PHARMACEUTICAL FORMULATIONS | October 2021 | January 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17492969 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT | October 2021 | October 2022 | Allow | 12 | 2 | 1 | Yes | No |
| 17483806 | WATER-BASED LIQUID COSMETIC | September 2021 | March 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17472783 | ELTROMBOPAG CHOLINE DOSAGE FORMS | September 2021 | December 2022 | Abandon | 15 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TCHERKASSKAYA, OLGA V.
With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner TCHERKASSKAYA, OLGA V works in Art Unit 1615 and has examined 790 patent applications in our dataset. With an allowance rate of 56.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner TCHERKASSKAYA, OLGA V's allowance rate of 56.3% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by TCHERKASSKAYA, OLGA V receive 2.52 office actions before reaching final disposition. This places the examiner in the 74% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by TCHERKASSKAYA, OLGA V is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +52.1% benefit to allowance rate for applications examined by TCHERKASSKAYA, OLGA V. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.3% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.5% of cases where such amendments are filed. This entry rate is in the 29% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 62.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 51% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 57.9% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 60.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 46.1% are granted (fully or in part). This grant rate is in the 40% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.